Myriad Genetics, Inc. (NASDAQ:MYGN) is set to announce first quarter earning results on Monday 9th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, MYGN to report 1Q21 loss of $ 0.3 per share.
For the full year, analysts anticipate top line of $ 654.84 million, while looking forward to loss of $ 0.18 per share bottom line.
Previous Quarter Performance
Myriad Genetics, Inc. reported loss for the fourth quarter of $ 0.31 per share, from the revenue of $ 93.20 million. The quarterly revenues contracted 49.97 percent compared with the same quarter last year. According to street consensus, MYGN was expected to report 4Q20 loss of $ 0.05 per share from revenue of $ 144.59 million. The top line results fell short of analysts by $ 51.39 million or 35.54 percent.
Stock Performance
On Friday, shares of Myriad Genetics, Inc. has traded high as $ 14.41 and has cracked $ 13.96 on the downward trend, reaching $ 14.29 with volume of 432.20 thousand shares.
According to the previous trading day, closing price of $ 14.29, representing a 53.03 % increase from the 52 week low of $ 9.24 and a 53.07 % decrease over the 52 week high of $ 30.13.
The company has a market capital of $ 1.07 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Myriad Genetics, Inc. will be hosting a conference call at 5:00 PM eastern time on 9th November 2020, to discuss its 1Q21 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website myriad.com
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis.
